Document:

EX-10.8

 IMAX CORPORATION 

EXHIBIT 10.8 

AMENDED EMPLOYMENT AGREEMENT 

This agreement amends the amended employment agreement (the “Agreement”) between Bradley J. Wechsler (the “Executive”) and
IMAX Corporation (the “Company”) dated July 1, 1998, as amended, on the same terms and conditions except as set out below: 
  

	1.	Term. The term of the Agreement is extended until December 31, 2009. 

  

	2.	Cash Compensation. The Executive shall be entitled to be paid base salary at the rate of $500,000 per year, plus a bonus of up to two times salary. Such bonus shall be at the discretion of the Board of Directors
and shall be based upon the success of the Company in achieving the goals and objectives set by the Board after consultation with the Executive. The Executive shall be considered for a bonus based upon performance during the years ending
December 31, 2008 and 2009. If the Executive’s employment is terminated without Cause prior to the end of the term, the Executive shall be entitled to no less than a pro-rata portion of his median bonus target (i.e. one times salary).

  

	3.	Stock Appreciation Rights. The Executive is hereby granted 600,000 stock appreciation rights (“SARS”) which shall entitle the Executive to receive in cash from the Company any increase in the fair
market value of the common shares of the Company from the fair market value thereof on December 31, 2007 to the date of exercise of the SARS. The SARS shall vest according to the following schedule: 150,000 on June 30, 2008, 150,000 on
December 31, 2008, 150,000 on June 30, 2009 and 150,000 on December 31, 2009. All SARS will have a 10-year term and, to the extent applicable, shall be governed by the provisions of the Stock Option Plan of the Company
(“SOP”), including for greater certainty, the provisions relating to the calculation of the fair market value of common shares of the Company; provided, however, that all vested SARS shall remain exercisable for a period of
three (3) years after either a termination without Cause of the Executive or the non-renewal of this Agreement, and for one (1) year after a resignation by the Executive. The vesting of all SARS shall be accelerated upon a “change of
control” as defined in the Agreement, and shall be governed, to the extent applicable, by the provisions in the Agreement regarding change of control. At any time and from time to time after vesting, but subject to the insider trading policy of
the Company in effect at that time which shall apply to the SARS as if they were securities covered thereby, the Executive shall be entitled to exercise some or all of the vested SARS by delivering notice of exercise in writing to the General
Counsel of the Company. Within 10 business days after receipt of such notice in writing, the Company shall pay to the Executive the amount by which the fair market value of the common shares of the Company has increased from the fair market value on
December 31, 2007 to the fair market value on the date of such notice, net of any applicable withholdings and any other amounts owing at that time by the Executive to the Company. Notwithstanding anything to the contrary contained herein, the
Company shall have the right but not the obligation to cancel at any time all, or from time to time any part, of the SARS, in any case upon notice in writing to the Executive and to replace the cancelled SARS with stock options, provided that
(i) such options or shares have no less favorable (to the Executive) material terms and conditions as, and are in such number as are of equivalent value to, the cancelled SARS, and (ii) the Company cannot replace cancelled SARS with stock
options if such options have a higher exercise price than the price of the common shares of the Company on December 31, 2007. 

	4.	The entering into this agreement shall not prejudice any rights or waive any obligations under any other agreement between the Executive and the Company. 

DATED as of December 31, 2007. 
  

					
	 “Bradley J. Wechsler”

	Bradley J. Wechsler
	
	IMAX CORPORATION
		
	Per:	 	 “Garth M. Girvan”

		 	Name:	 	Garth M. Girvan
		 	Title:	 	DirectorEX-10.11

 IMAX CORPORATION 

EXHIBIT 10.11 

AMENDING AGREEMENT No.2 
 This
Amendment to Services Agreement dated as of (the “Amending Agreement”) is made between:  
 IMAX CORPORATION, a corporation
incorporated under the laws of Canada (hereinafter referred to as the “Company”), 
 and 

BRAD WECHSLER (the “Executive”) 
 WHEREAS,
the Company wishes to enter into this Amending Agreement No. 2 to amend and extend the Services Agreement dated as of December 11, 2008 , as amended by Amending Agreement dated February 14, 2011, (collectively the
“Agreement”). 
 NOW THEREFORE, in consideration of the premises and of the mutual covenants and agreements herein contained, the parties
hereto agree as follows: 
  

	1.	The following will be added as the final “Whereas clause” on page 1 of the Agreement: 

“WHEREAS the Board and the Chairman each recognize and acknowledge their fiduciary duties to the Company.” 

 

	2.	Section 1 of the Agreement shall be deleted and replaced with the following: 

 1. Term.
The term of the Agreement shall begin on the Effective Date and continue until such time as the Board determines to terminate the services of the Chairman. Any such termination shall be communicated to Chairman with ninety (90) days written
notice, unless termination is made for Cause, as that term is defined in the Employment Agreement, in which case no notice shall be required. Unless the Chairman’s services are terminated as aforesaid, the Board agrees continue to nominate him
for re-election to the Board and to make all reasonable efforts to solicit shareholder approval of his re-election to the Board. 
  

	3.	Section 3 of the Agreement shall be deleted and replaced with the following: 

 3.
Compensation and Benefits. During the Term, Chairman shall receive a cash stipend of $230,000 for each year served as Chairman of the Board, payable in equal parts fifteen (15) days after the end of each calendar quarter (the “Fee”).
The Company shall also reimburse Chairman for all reasonable out-of-pocket expenses in the performance of his obligations under this Agreement for which documentation reasonably satisfactory to IMAX is provided, including expenses relating to
Chairman’s travel and performance of duties outside of his office in New York. The Company shall additionally provide Chairman with reimbursement of all reasonable automobile expenses, office space in the Company’s New York office and an
assistant throughout the Term. 

	4.	General. Except as amended herein, all other terms of the Agreement shall remain in full force and unamended. 

DATED as of April 1, 2013 

AGREED AND ACCEPTED: 
  

	
	
	/s/ Bradley J. Wechsler
	Bradley J. Wechsler
	
	IMAX CORPORATION
	
	/s/ Robert D. Lister
	 Robert D. Lister
  

Chief Legal Officer
 Chief Business Development
Officer

	
	/s/ Joseph Sparacio
	 Joseph Sparacio
  

Executive Vice President and
 Chief Financial
OfficerEX-10.16

 IMAX CORPORATION 

EXHIBIT 10.16 

AMENDED EMPLOYMENT AGREEMENT 

This agreement amends the amended employment agreement (the “Agreement”) between Richard L. Gelfond (the “Executive”) and
IMAX Corporation (the “Company”) dated July 1, 1998, as amended, on the same terms and conditions except as set out below: 
  

	1.	Term. The term of the Agreement is extended until December 31, 2009. 

  

	2.	Cash Compensation. The Executive shall be entitled to be paid base salary at the rate of $500,000 per year, plus a bonus of up to two times salary. Such bonus shall be at the discretion of the Board of Directors
and shall be based upon the success of the Company in achieving the goals and objectives set by the Board after consultation with the Executive. The Executive shall be considered for a bonus based upon performance during the years ending
December 31, 2008 and 2009. If the Executive’s employment is terminated without Cause prior to the end of the term, the Executive shall be entitled to no less than a pro-rata portion of his median bonus target (i.e. one times salary).

  

	3.	Stock Appreciation Rights. The Executive is hereby granted 600,000 stock appreciation rights (“SARS”) which shall entitle the Executive to receive in cash from the Company any increase in the fair
market value of the common shares of the Company from the fair market value thereof on December 31, 2007 to the date of exercise of the SARS. The SARS shall vest according to the following schedule: 150,000 on June 30, 2008, 150,000 on
December 31, 2008, 150,000 on June 30, 2009 and 150,000 on December 31, 2009. All SARS will have a 10-year term and, to the extent applicable, shall be governed by the provisions of the Stock Option Plan of the Company
(“SOP”), including for greater certainty, the provisions relating to the calculation of the fair market value of common shares of the Company; provided, however, that all vested SARS shall remain exercisable for a period of
three (3) years after either a termination without Cause of the Executive or the non-renewal of this Agreement, and for one (1) year after a resignation by the Executive. The vesting of all SARS shall be accelerated upon a “change of
control” as defined in the Agreement, and shall be governed, to the extent applicable, by the provisions in the Agreement regarding change of control. At any time and from time to time after vesting, but subject to the insider trading policy of
the Company in effect at that time which shall apply to the SARS as if they were securities covered thereby, the Executive shall be entitled to exercise some or all of the vested SARS by delivering notice of exercise in writing to the General
Counsel of the Company. Within 10 business days after receipt of such notice in writing, the Company shall pay to the Executive the amount by which the fair market value of the common shares of the Company has increased from the fair market value on
December 31, 2007 to the fair market value on the date of such notice, net of any applicable withholdings and any other amounts owing at that time by the Executive to the Company. Notwithstanding anything to the contrary contained herein, the
Company shall have the right but not the obligation to cancel at any time all, or from time to time any part, of the SARS, in any case upon notice in writing to the Executive and to replace the cancelled SARS with stock options, provided that
(i) such options or shares have no less favorable (to the Executive) material terms and conditions as, and are in such number as are of equivalent value to, the cancelled SARS, and (ii) the Company cannot replace cancelled SARS with stock
options if such options have a higher exercise price than the price of the common shares of the Company on December 31, 2007. 

	4.	The entering into this agreement shall not prejudice any rights or waive any obligations under any other agreement between the Executive and the Company. 

DATED as of December 31, 2007. 
  

					
	 “Richard L. Gelfond”

	Richard L. Gelfond
	
	IMAX CORPORATION
		
	Per:	 	 “Garth M. Girvan”

		 	Name:	 	Garth M. Girvan
		 	Title:	 	Director

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00226-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00226-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00226-of-00352.parquet"}]]